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Abstract. Phaeochromocytomas and functioning para- 
gangliomas are rare tumours in childhood and adoles- 
cence. We review our experience of 43 cases (24 men, 
19 women) who were first diagnosed at the age of 
<18 years. All patients were evaluated at some point 
in their illness with iodine 131 metaiodobenzylguanidine 
(131I_mIBG ) scintigraphy. Eight patients (19%) had bi- 
lateral adrenal tumours, 12 (28%) had solitary extra- 
adrenal tumours, and 8 (19%) had multiple tumours. 
In 10 patients (23%), the tumours were associated with 
a familial neurocristopathic syndrome. Thirteen of 24 
(54%) unifocal tumours which were initially considered 
to be benign ultimately proved to be multi-focal and/or 
malignant. The final prevalence of malignancy was 60% 
- 26 patients, of whom only 15 (57%) had obviously 
malignant tumours at the time of diagnosis. Primary 
tumour size _> 5 cm was more commonly associated with 
a malignant course in adrenal but not extra-adrenal tu- 
rnouts. No other clinical, biochemical or morphological 
characteristic was significantly associated with malig- 
nancy. Although the high prevalence of malignancy in 
this series at least partly reflects referral bias, the need 
for lifelong follow-up of these patients is underscored. 
13II-mIBG scintigraphy was positive in 36patients 
(84%), with a somewhat lower false-negative rate (12%) 
than X-ray computed tomography (20%). Eight patients 
with malignant tumours received therapeutic doses of 
13q-mIBG, with partial tumour responses in 3. Thus, 
aalI-mIBG is an efficacious, non-invasive, localising 
agent and may be considered as a palliative therapeutic 
agent when alternatives have failed. 
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Introduction 
Phaeochromocytomas are catecholamine-secreting tu- 
mours arising from adrenal medullary tissue which pro- 
duce a highly variable clinical syndrome typically char- 
acterised by the triad of hypertension, headache and 
sweating (Manger and Gifford 1982; Bravo and Gifford 
1984; Shapiro and Fig 1989). Hypercatecholaminaemia 
and an identical syndrome may also result from func- 
tioning tumours arising in extra-adrenal chromaffin tis- 
sue within sympathetic and other autonomic ganglia and 
paraganglia (including such specialised structures as the 
carotid and aortic bodies); such tumours have variously 
been termed "extra-adrenal phaeochromocytomas" and 
"functioning paragangliomas" - the latter designation 
has been recommended by the Armed Forces Institute 
of Pathology (Glenner and Grimley 1974). 
Phaeochromocytomas and functioning paraganglio- 
mas are rare turnouts, with an estimated prevalence of 
0.1%-0.5% of the hypertensive population and a peak 
incidence in the 3rd to 4th decades (Manger and Gifford 
1982; Bravo and Gifford 1984; Shapiro and Fig 1989). 
It is generally held that approximately 10% of turnouts 
are extra-adrenal, 10% of patients have multiple tu- 
rnouts, 10% of turnouts are malignant, and 10% occur 
in childhood. Although the reported incidence of malig- 
nant tumours in childhood appears to be similar to that 
in adults, over 50% of children with the phaeochromo- 
cytoma syndrome have extra-adrenal, bilateral adrenal 
or multiple tumours (Hume 1960; Stackpole et al. 1963; 
Melicow 1977; Kaufman et al. 1983). Phaeochromocyto- 
mas and functioning paragangliomas are components 
of the autosomal dominant multiple endocrine neoplasia 
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(MEN) syndromes types 2a (medullary thyroid carcino- 
ma, parathyroid hyperplasia or adenoma and phaeo- 
chromocytoma)  and 2b (marfanoid habitus, mucosal 
neuromata,  medullary thyroid carcinoma and phaeoch- 
romocy toma  and may occasionally appear  in isolation 
as an autosomal dominant  familial syndrome without 
other features of  M E N  (Glowniak et al. 1985). They are 
also associated with the neurocutaneous syndromes of  
yon Recklinghausen's (neurofibromatosis) and Lindau-  
von Hippel disease (retinal and cerebellar angiomatosis 
and multiple hamar tomas)  more  commonly  than in the 
general population. Finally, paragangliomas may  occur 
in association with gastric leiomyosarcomas and pulmo- 
nary chondromas to make up Carney's  triad (Carney 
1983). In all these syndromes, affected children are dis- 
proport ionately over represented. Because of  the rarity 
of  the phaeochromocytoma syndrome in the paediatric 
and adolescent age group, series reported f rom single 
institutions are necessarily small. We present the com- 
bined experience of  two tertiary referral centres in evalu- 
ating patients whose original tumours  were diagnosed 
in childhood. 
Patients and methods 
In this retrospective study, patients in whom the diagnosis of (adre- 
nal) phaeochromocytoma or functioning paraganglioma (extra-ad- 
renal phaeochromocytoma) was made at or before the age of 
18 years were identified from our data base of patients referred 
to the University of Michigan Medical Center, Ann Arbor, Michi- 
gan, or the University of Munster, FRG, for evaluation with io- 
dine 131 metaiodobenzylguanidine (131I-mIBG) in the 5 years end- 
ing December 1985. (After 1985, the more widespread availability 
of mIBG outside these institutions resulted in a change in our 
referral base.) All studies were performed with the written consent 
of the patients or their legal guardians, according to protocols 
approved by the institutions' research ethics committees. 
Upon referral, a history was taken and a physical examination 
performed with all patients, with particular attention to family 
history or clinical evidence of familial syndromes including MEN 
and neurocutaneous syndromes. Blood samples were collected for 
the measurement of plasma catecholamine (adrenaline and nor- 
adrenaline) levels in resting, supine, fasted patients through an 
indwelling intravenous cannula which had been inserted at least 
30 min before sampling. Plasma catecholamines were measured by 
a radioenzymatic assay (Peuler and Johnson 1977). The 12- or 
24-h urinary catecholamine and metanephrine (metanephrine and 
normetanephrine) levels were determined by a fluorimetric assay 
(Von Euler and Lishajko 1959), and urinary vanillylmandelic acid 
(VMA) levels were measured spectrophotometrically (Pisano et al. 
1962). 
Prior to 13~I_mIBG scanning, all patients received three drops 
of a saturated solution of potassium iodide (SSKI, 120 mg iodide) 
per day for 1 week starting from the day before injection to block 
thyroidal uptake of free radioiodide. 131I-mIBG [specific activity 
48 GBq (1.3 Ci)/mmol] was given by slow intravenous injection 
in a dose of 18.5 MBq (0.5 mCi)/1.73 m z body surface area, to 
a maximum dose of 37 MBq (1.0 mCi). At 24, 48 and 72 h after 
injection, overlapping scintigrams of the whole body were obtained 
using a wide field-of-view gamma-camera fitted with a high-energy, 
parallel-hole collimator and interfaced to a computer. Images were 
acquired for 100000 counts or 20 min per view. All scans were 
reported by experienced observers according to criteria previously 
described (Nakajo et al. 1983; Shapiro et al. 1985). The location 
of areas of abnormal uptake was defined by using external surface 
markers or, when necessary, "internal markers" in the form of 
99mTc-labelled radiopharmaceuticals or 2°1T1. Therapeutic doses 
of 131I-mIBG [specific activity 300400 GBq (8-11 Ci)/mmol], ad- 
ministered to patients with malignant disease unreponsive to other 
modalities, were based on dosimetric calculations made with a 
"tracer" dose of 37 MBq (1.0 mCi)/l.73 m z of body surface area 
and external standard sources (Shulkin et al. 1988). 
Statistical comparisions were carried out using the unpaired 
Student's t test or the Mann-Whitney U test and the X 2 test; corre- 
lations were by simple linear regression. Statistical significance was 
accepted at the 5% level. 
Results 
Among 206 patients of  all ages known or subsequently 
proven to have phaeochromocytomas  or functioning 
paragangl iomas referred to the University of  Michigan 
or University of  Munster in the period 1980-1985 for 
evaluation with 131I-mIBG, 43 (21%) had their initial 
diagnoses made at the age of  18 years or younger 
(Fig. 1). Some of  these patients have been the subjects 
o f  earlier individual case reports (Shapiro et al. 1984; 
Glowniak et al. 1985; Impera to-McGinley  et al. 1987; 
Shulkin et al. 1987). The median age at initial presenta- 
tion was 12.5 years (mean 13.0, range 5-18). There were 
24 men (mean age at presentation_+ SD, 12.9 + 3.2 years) 
and 19 women (mean age at p resen ta t ion+SD,  13.0_+ 
2.9 years; P=0.50) .  The majori ty of  patients (38, 88%) 
were white; 3 were black, and 2 were Hispanic. The 
mean age at presentation (_+ SD) of  patients with adrenal 
tumours (13.4 + 2.7 years) was not  significantly different 
f rom that  of  patients with extra-adrenal or multiple tu- 
mours (12.4_+3.4 years), and that  of  patients with tu- 
mours which ultimately proved to be malignant  (13.0_+ 
3.4 years) was similar to that  of  patients with benign 
tumours (12.9 + 2.4 years). The interval between diagno- 
sis and referral to our institutions ranged f rom 0 to 
33.5 years (median 4.0 years). The patients had been fol- 
lowed-up for a median period of  6 years since diagnosis 
(range 1-34 years). Durat ion  of  follow-up was signifi- 
cantly longer for patients ultimately diagnosed as having 
malignant  tumours  (1-34 years, median 10.5 years) than 
for those thought to have benign tumours (1 17 years, 
median 4.5 years; P = 0.004). 
Clinical features 
At least one of  the symptoms classically associated with 
catecholamine excess - namely, hypertension (34 pa- 
tients, 79%), headache (19 patients, 44%) and sweating 
(18 patients, 42%) - were present in the majority of  pa- 
tients at presentation (Table 1). Hypertension was non- 
paroxysmal  in the majority of  cases, although two pa- 
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Fig. 1. Age at presentation (years) 
tients presented in hypertensive crisis. The triad of  hy- 
pertension, headache and sweating occurred in 10 pa- 
tients (23%). 
One patient presented with congestive cardiac failure 
due to catecholamine cardiomyopathy which resolved 
after successful surgery for her phaeochromocytoma;  
she also had the triad described above. Her case is de- 
scribed in detail elsewhere (Imperato-McGinley et al. 
1987). Four  patients, all with malignant tumours, had 
erythrocytosis; all were hypertensive at presentation, 
and one is the subject of  a recent case report  (Shulkin 
et al. 1987). Four  patients had neurological symptoms 
other than headache associated with hypertension: visu- 
al disturbance (2), encephalopathy (1) and gait distur- 
bance (1). 
Four  patients had their tumours discovered inciden- 
tally. In one, a hypertensive black women, a benign para- 
ganglioma of  the organ of  Zuckerkandl was discovered 
at age 17 during laparotomy for an abdominal mass 
which proved to be a leiomyosarcoma; 9 years later, she 
was found to have a malignant intrathoracic paragang- 
lioma. This patient exhibited Carney's triad. Another 
patient, a normotensive white man, presented at the age 
of  13 years with abdominal pain and an enlarging pelvic 
mass; laparotomy disclosed a complex pelvic lymphan- 
giomyoma and an incidental benign pelvic paraganglio- 
ma. His catecholamine levels remained elevated postop- 
eratively, and he was subsequently found to have an 
additional benign juxta-adrenal paraganglioma as well 
as recurrent visceral lymphangiomyomatosis.  This asso- 
ciation has not, to our knowledge, been described pre- 
viously. The patient is an adopted child, and his family 
history is unknown. In the third patient, a large mass 
apparently arising from the aortic bifurcation was noted 
during an appendectomy; palpation of  this mass resulted 
in a dramatic rise in blood pressure - she had not  pre- 
viously been known to have hypertension. The last, 
asymptomatic patient with bilateral adrenal phaeochro- 
mocytomas was initially discovered at age 17 during bio- 
chemical screening of  a kindred with Lindau-von Hippel 
disease; he developed skeletal and extradural metastases 
19 years later. 
Table 1. Clinical features 
Final diagnosis 
Benign Malignant 
(n = 17) (n = 26) 
Total 
Symptoms 
Hypertension 11 23 34 
Headache 8 11 19 
Sweating 8 10 18 
Triad a 4 6 10 





Visual disturbance 2 
Gait disturbance 1 
Encephalopathy 1 
Catecholamine cardiomyopathy l 
Miscellaneous 6 
Delay in diagnosis (n) 6 3 9 
Range (years) 1-2 2-8 1-8 
Syndromes 
Familial phaeochromocytoma: 
Definite - 5 5 
Possible 2 1 3 
MEN-2b 1 b 1 2 
Neurofibromatosis 1 - 1 
Lindau-von Hippel 1 1 2 
Carney's triad - 1 1 
MEN, multiple endocrine neoplasia 
Hypertension+headache+sweating 
b Bilateral adrenal medullary hyperplasia 
Phaeochromocytomas were a manifestation of  
MEN-2b in 2 patients, Lindau-von Hippel disease in 
2 (including the patient mentioned above) and neurofi- 
bromatosis in 1. Five patients - all with malignant tu- 
mours - had a definite family history of  phaeochromocy- 
tomas consistent with an autosomal dominant  inheri- 
tance but not  associated with neurocutaneous or M E N  
syndromes. Three additional patients (2 with benign and 
1 with malignant tumours) had a possible family history, 
suggested by a history of  hypertension and unexplained 
sudden death of  a first-degree relative in young adult- 
hood. Thus, at least 10 patients (23%) - and possibly 
up to 13 - had phaeochromocytomas or functioning par- 
agangliomas associated with an autosomal dominant,  
familial syndrome. 
The diagnosis of phaeochromocytoma was made 
within 1 year of  presentation in the majority of  patients. 
There was a delay in diagnosis of  1-8 years in 9 patients 
(14%). 
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Table 2. Plasma and urine biochemistry results 
Normal Mean Median Minimum Maximum Percentage 
abnormal 
Plasma (n = 37) 
Adrenaline (pg/ml) < 100 
Noradrenaline (pg/ml) < 500 
Urine (n = 42) 
Adrenaline (gg/24 h) < 30 
Noradrenaline (gg/24 h) < 110 
Metanephrine (gg/24 h) < 85 
Normetanephrine (gg/24 h) < 165 
VMA (mg/24 h) < 7 
198 96 16 1157 43 
7131 2661 205 54253 97 
43 12 <5 611 28 
872 530 24 4493 90 
88 18 4 1043 21 
1113 212 6 9739 57 
36 24 1.7 146 79 
VMA, vanillylmandelic acid 
Biochemical findings 
The results of plasma and urinary catecholamine and 
metabolite estimations are summarised in Table 2. There 
were no significant differences in any of these measure- 
ments between benign and malignant or between adrenal 
and extra-adrenal tumours. There were significant corre- 
lations between plasma and urinary noradrenaline ( r=  
90, P < 0.001), plasma adrenaline and noradrenaline (r = 
0.79, P<0.001) and urinary adrenaline and noradrena- 
line (r=0.69, P<0.001) levels. Urinary VMA and total 
metanephrine levels correlated weakly (r=0.39, P =  
0.0t8). Only 1 patient had normal plasma and urinary 
biochemistry results; she was a 13-year-old girl with 
MEN-2b and surgically proven bilateral adrenal medul- 
lary hyperplasia detected by ~ 311-mIBG scan. No patient 
with abnormal urinary biochemistry data had normal 
plasma catecholamine levels. The 4 patients with normal 
urinary noradrenaline levels also had normal urinary 
adrenaline and metabolite levels, i.e. measurement of  uri- 
nary metabolites did not improve the sensitivity of uri- 
nary catecholamine estimation. The combination of uri- 
nary VMA and normetanephrine estimations was a sen- 
sitive as measurement of urinary catecholamine excre- 
tion. 
Pathology 
Tumours arose in the adrenal glands in 24 patients (right 
adrenal in 10, left adrenal in 6, bilateral in 8); in 3 pa- 
tients with bilateral adrenal tumours, the tumours were 
metachronous (Table 3). Nineteen patients had extra-ad- 
renal or multiple (other than bilateral adrenal) tumours. 
The sites of presenting extra-adrenal tumours were per- 
iadrenal or perirenal in 6, para-aortic (including the or- 
gan of Zuckerkandl) in 6, the pelvis in 4 (including one 
bladder tumour), pericardiac in 1, paraspinal in 1 and 
multiple tumours at presentation in 1 (the patient de- 
scribed above). There were no significant sex differences 
between patients presenting with adrenM (13 men, 
11 women) or extra-adrenal tumours (11 men, 8 wom- 
en). Six patients with apparently solitary, benign tu- 
mours at initial operation went on to develop additional 
benign tumours (3 adrenal, 3 extra-adrenal), 1-] 6 years 
(median 3.3 years) later (Fig. 2). 
Some 26 patients (60%) ultimately proved to have 
malignant tumours. Malignancies were significantly 
more common among men (18) than women (8; P =  
0.028). Fourteen (54%) of  the malignancies occurred in 
patients who presented initially with primary adrenal 
tumours (bilateral in 3). Thus, malignancies were as like- 
ly to arise from adrenal (14/24, 58%) as from extra- 
adrenal primaries (12/19, 63%). Only 15 tumours were 
obviously malignant at the time of initial diagnosis; the 
remainder were apparently benign but developed malig- 
nant local recurrences or distant metastases 0.5-26 years 
after initial surgery (Fig. 2). Malignant behaviour was 
manifest as local spread in 23, spread to lymph nodes 
in 15 and distant metastases to bone in 18, lung in 8, 
liver in 3 and other sites in 8. Most patients with malig- 
nant tumours (24, 92%) developed multiple metastatic 
sites. Local recurrences of  the primary tumour preceded 
more distant metastases in 4 patients by 2 (2 cases), 12 
and 14 years. Four deaths were recorded at 2, 6, 14 and 
30 years after initial presentation. 
A record of the size of the presenting tumour was 
available for 33 patients (77%), whose tumours ranged 
from 1.0 to 20.0 cm in maximum diameter (median 
6.0 cm; mean_+SD, 6.0+_3.7 cm). There was no signifi- 
cant difference in size between primary adrenal (6.9_+ 
4.4 cm, n =  19) and extra-adrenal tumours (4.8_+2.2 cm, 
n=14 ;  P=0.125). However, malignant tumours were 
significantly larger than benign ones (7.4_+ 4.1 cm, n = 18 
vs. 4.3_+2.3 cm, n =  15, respectively; P=0.015). Fifteen 
of 18 malignant tumours were 5 cm or more in maxi- 
mum diameter, whereas 10 of 15 benign tumours were 
less than 5 cm in diameter (P<0.01). All 10 malignant 
adrenal primaries were > 5 cm, while 7 of  9 benign.adre- 
nal phaeo.chromocytomas were <5  cm (P<0.01);  be- 
nign and malignant extra-adrenal tumours were of com- 






n Final diagnosis n 
Adrenal (n = 24) 
Unilateral 19 
(R 11, L 8) 
Bilateral 5 
Benign 14 Unilateral adrenal, 6 
benign 
Malignant 5 Unilateral adrenal, 9 
malignant 
Bilateral adrenal, 2 
benign 




Benign 5 Bilateral adrenal, 2 
benign 
Bilateral adrenal, 3 
malignant 
Extra-adrenal (n = 18) 
Para-aortic a 6 Benign 5 Extra-adrenal, 1 
benign 






Perirenal 4 Benign 2 Extra-adrenal, 1 
benign 




Periadrenal 2 Malignant 2 Extra-adrenal, 2 
malignant 
Pelvic 4 Benign 1 Multiple, 1 
benign 
Malignant 3 Extra-adrenal, 3 
malignant 
Pericardiac 1 Benign 1 Extra-adrenal, 1 
benign 
Paraspinal 1 Malignant 1 Extra-adrenal, 1 
malignant 
Multiple i Malignant 1 Multiple, 1 
malignant 
" Includes tumours arising in the organ of Zuckerkandl 
parable size (5/8 malignant tumours > 5 cm, 3/6 benign 
tumours < 5 cm). 
There was no correlation between tumour size and 
plasma or urinary catecholamine or metabolite levels. 
Role  o f  i s 11-mlBG 
The 131I-mlBG whole-body scan was true-positive in 
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Fig. 2. Time to first metastasis (malignant tumours, black bars) 
or second tumour (benign tumours, hatched bars) since diagnosis 
(years) 
Table 4. Tumour localisation by iodine 131 metaiodobenzylguani- 
dine (131I-mibg) and computed tornography (CT) scanning 
1311-mibg CT a 
True-positive 33 27 
Equivocally positive b 3 3 
False-positive 2 0 
True-negative 0 2 
False-negative 5 8 
" Three patients did not undergo CT scanning; 2 of these had 
true-positive ultrasound scans 
b Detected some, but not all, subsequently proven disease foci 
disease detected) (Table 4). Three of  these patients had 
equivocal computed tomography (CT) scan findings and 
6 had false-negative CT scans. (Three patients did not 
undergo CT study; 2 of  them had positive results on 
ultrasound examination). Two patients had false-nega- 
tive and 2 had equivocally abnormal venous sampling 
studies. 131I-mIBG scanning found some, but not all, 
sites of  disease in a further 3 patients (" equivocally posi- 
t ive" studies) - bone metastases were missed in 2 pa- 
tients and pulmonary metastases in 1. All 3 had positive 
CT scans. 
Five patients had false-negative 131I-mIBG scans, 3 
of  whom had true-positive CT scans (2 of  these 3 also 
had positive bone scans). One of  the remaining 2 pa- 
tients had a cervical disease focus located by venous 
sampling. The 5th patient, who was asymptomatic but 
had developed elevated catecholamine levels 3 years 
after excision of  a paraganglioma of  the right renal hi- 
lum, defied all attempts at localisation, including venous 
sampling, until 4 years later when he re-presented with 
a metastasis in L4 and cord compression• 
Finally, 2 patients had apparently false-positive 131I_ 
mIBG scans. In 1, the scan suggested an abnormally 
increased right adrenal uptake in a patient who 5 years 
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previously had an apparently benign tumour of the or- 
gan of Zuckerkandl but persistently elevated catechol- 
amine levels and intermittent hypertension. The CT scan 
was negative, and vein sampling was equivocal; the adre- 
nals appeared normal at re-exploration. The 2nd patient 
developed hypertension and elevated catecholamine lev- 
els 16 years after resection of a paraganglioma of the 
organ of Zuckerkandl; the 13~I-mIBG scan suggested 
that abnormalities were present in the left supraclavicu- 
lar and left sacroiliac regions. This was not confirmed 
by subsequent CT scans, but an ultrasound examination 
suggested the presence of tumours at the junction of 
the left subclavian and jugular veins and adjacent to 
the left ovary. Exploration of the neck and thorax were 
negative; the pelvis was not explored. 
Eight of the patients with malignant phaeochromo- 
cytomas received 1-5 therapeutic doses of a31I-mIBG; 
the maximum total dose received was 44.6GBq 
(1205 mCi). Three patients showed a partial response, 
4 had no positive response (but no evidence of disease 
progression), and one had progressive disease and later 
died. 13tI-mIBG therapy was never curative. Two pa- 
tients have also received combination chemotherapy, 
with a partial response in 1. 
Discussion 
Phaeochromocytomas and functioning paragangliomas 
are rare tumours of childhood and adolescence. Between 
1954 and 1980, there were only 3 patients with phaeo- 
chromocytoma and 4 with paraganglioma recorded in 
the Manchester Childhood Tumour Registry (Birch 
1983; Marsden 1983). This contrasts with an incidence 
of neuroblastoma of 168 (6.2 per million) and an overall 
prevalence of malignancies of 2688 (99.3 per million). 
Melicow (1977) reported 11 cases of childhood phaeoch- 
romocytoma/paraganglioma among 100 cases studied at 
a single institution. In the 20-year experience of over 
500 hypertensive children at the Children's Hospital 
Medical Center, Cincinnati, Ohio (Loggie 1985) only 
4 phaeochromocytomas, 1 adrenal ganglioneuroma and 
1 brachial plexus paraganglioma were found. Similarly, 
the 20-year experience of the Toronto Hospital for Sick 
Children amounted to a total of 8 cases (Stringel et al. 
1980), and the 30-year experience of the Mayo Clinic 
came to 18 cases aged 17 years or younger (Telander 
etal. 1985). At the Vanderbilt University Medical 
Center, only 2 of 69 patients with phaeochromocytoma 
were aged 18 years or less (Scott and Halter 1984). In 
their complete review of the world literature to 1962, 
Stackpole et al. (1963) found a total of 91 cases of pae- 
diatric (symptom onset at age 15 years or younger) 
phaeochromocytoma (including extra-adrenal tumours) 
and added 9 cases of their own. Hume's (1960) earlier 
large review had found 85 published cases. The findings 
of these series, as well as our own, are summarised in 
Table 5. All of the larger series of phaeochromocytoma 
in childhood and adolescence thus far have emphasised 
the preponderance of affected males, the predominance 
of sustained rather than paroxysmal hypertension, the 
propensity for bilateral adrenal, extra-adrenal and multi- 
ple turnouts and the possibility of familial occurrence. 
It is obvious from Table 5 that the present series has 
an unusually high prevalence of malignant turnouts; this 
is, at least in part, a reflection of referral bias, inasmuch 
as more "difficult" cases with suspected extra-adrenal 
or multi-focal (either metastatic malignant or multiple 
benign) disease were more likely to have been referred 
for tumour localisation with 131I-mIBG whole-body 
scintigraphy (see below). Nonetheless, it should be re- 
called that only 15 (35%) of our patients were thought 
to have malignant tumours at the time of diagnosis (Ta- 
ble 3); the malignant potential of the tumours in the 
remaining 11 patients only became evident after a some- 
times protracted follow-up. Similarly, 21 patients (49%) 
had apparently solitary, benign tumours at presentation 
(14 adrenal, 7 extra-adrenal), but 6 of these (29%) subse- 
quently went on to develop additional benign tumours. 
The importance of (indefinite) follow-up of children or 
adolescents with phaeochromocytoma, in order to detect 
the later development of multi-focal or metastatic dis- 
ease, has been emphasized by others (Stackpole et al. 
1963; Kaufman etal. 1983). Scott and Halter (1984) 
have extended this recommendation to include all pa- 
tients with phaeochromocytomas, since 5 of their 9 pa- 
tients (aged 31-61 years) with malignant tumours were 
thought intially to have benign tumours but developed 
recurrent and/or metastatic disease 1-6 years after initial 
surgery. In a review of the early University of Michigan 
experience with 13 II_mIBG ' Beierwaltes (1987) estimated 
the cumulative incidence of detection of metastases of 
malignant phaeochromocytoma to be 5%/year for the 
first 9 years and 0.6%/year subsequently; metastases 
were present at diagnosis in only 47% of patients with 
malignant phaeochromocytoma. In the present series, 
since the duration of follow-up for patients with a "fi- 
nal" diagnosis of benign turnout was significantly short- 
er than for those with malignant tumours, it may be 
anticipated that the ultimate prevalence of malignancy 
will be even higher. 
The patient's age at presentation or diagnosis, the 
clinical presentation (with the possible exception of er- 
ythrocytosis or the presence of unequivocal metastases), 
the biochemical findings and the location of the tumour 
with which the patient presented were not predictive of 
a subsequent malignant course. Men were found more 
commonly among patients with malignant tumours, and 
indeed male predominance appears to be a feature of 
most series of childhood phaeochromocytoma (Table 5), 
although the sex difference overall in the present series 
was not statistically significant. Large primary turnout 
size ( > 5 cm) was significantly associated with malignan- 
cy, at least for adrenal tumours. Medeiros et al. (1985) 
also found malignant adrenal phaeochromocytomas to 
be significantly larger than benign tumours, and Scott 
Table g. Comparison of present series with literature 
Hume 1960 Stackpole et al. Mel icow Kaufman et al. 1983 Scott and Present 
1963 1977 (Telander et al. 1985) a Halter 1984 study 
No. of cases 85 100 11 16 (18) 8 43 
Male:female 52:31 68:32 7:4 "2:1" 7:1 24:19 
Sustained hypertension 64/69 - - 9/12 4/8 32/34 
93% 88% 75% 50% 94% 
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Tumor location 
Solitary adrenal 36/76 - 5 6 6 15 d 
47% 49% 45% 38% (33%) 75% 35% 
Bilateral adrenal 18/76 - 1 3 1 8 d 
24% 20% 9% 19% (17%) 12% 19% 
Solitary extra-adrenal 11/76 - 2 4 (6) - 12 d 
14% 19% 18% 25% (33%) 28% 
Multiple 11/76 - 3 3 1 8 d 
14% 12% 27% 19% (17%) 12% 19% 
Malignant 3/85 n.s. b 1 1 (3) 1 26 
3.5% 9% 6% (17%) 12% 60% 
Syndromes 
Familial phaeochromocytoma 7 2/9 ~ 3 2 - 5 
Neurofibromatosis 1 - 1 - - 1 
Lindau-von Hippel - - - 2 2 
MEN-2a - - - 2 2 - 
MEN-2b - - - 1 - 2 
Carney's triad . . . . .  1 
a Two additional cases reported in Telander et al. 1985. Numbers in parentheses include these 2 cases 
b Not specified 
Two of the authors' 9 additional cases were siblings 
a Final diagnosis 
and Halter (1984) noted that all their malignant tumours 
were > 6 cm in diameter. 
Because of  the nature of  the present series, no mean- 
ingful estimate can be made of  the sensitivity or specifici- 
ty of  the diagnostic or localising procedures used. Never- 
theless, it may fairly be concluded (Table 2) that plasma 
and urinary noradrenaline estimations are the most use- 
ful diagnostic biochemical measurements; neither uri- 
nary metanephrine levels nor urinary VMA levels in iso- 
lation were as frequently positive as plasma or urinary 
catecholamine (specifically, noradrenaline) levels. These 
findings are somewhat at odds with the recent Mayo 
Clinic data in children (Kaufman et al, 1983) but consis- 
tent with those of  Bravo and Gifford (1984) for phaeo- 
chromocytomas in general. 
An iodinated aralkylguanidine, m I B G  is structurally 
similar to guanethidine and noradrenaline and is taken 
up into the adrenal medulla and similar tissue by the 
neuronal catecholamine reuptake mechanism and is 
stored in catecholamine storage vesicles (Wieland et al. 
1981). Its application in the localisation of  phaeochro- 
mocytomas,  paragangliomas, neuroblastomas and other 
tumours of  putative neural crest origin has been the sub- 
ject of  several recent reviews (Shapiro et al. 1985, 1989; 
McEwan et al. 1985; Mauer and Mastrangelo 1987; Sha- 
piro and Sisson 1988). The overall accuracy of  mIBG 
scintigraphy for tumour localisation in the present series 
is comparable with that recorded elsewhere in the litera- 
ture. The false-negative rate for CT scanning (20%) was 
higher than that for mIBG scanning (12%). Whole-body 
scanning with mIBG has been shown to be superior to 
CT scanning for the localisation of  extra-adrenal, multi- 
focal and metastatic malignant phaeochromocytomas 
and paragangliomas (reviewed in McEwan et al. 1985; 
Shapiro et al. 1989). 
The somewhat disappointing results of  131I-mIBG 
therapy in this group of  patients is consistent with our 
overall experience in 28 patients with malignant 
phaeochromocytomas (Shapiro and Sisson 1988), at 
least 8 of  whom showed partial objective responses (5 
of  these subsequently relapsed), 10 had stable disease, 
and 10 suffered from progressive disease. The results 
of 13 ~I-mIBG therapy for neuroblastoma are a little bet- 
ter (Mauer and Mastrangelo 1987; Shapiro and Sisson 
1988; Shapiro et al. 1989), possibly reflecting the rela- 
tively greater radiosensitivity of  neuroblastomas. 
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In conclus ion ,  p h a e o c h r o m o c y t o m a s  and  func t ion-  
ing p a r a g a n g l i o m a s  are  ra re  t umour s  o f  c h i l d h o o d  and  
adolescence.  Unl ike  their  adu l t  coun te rpa r t s ,  affected 
chi ldren  p resen t  m o r e  c o m m o n l y  with  sus ta ined  r a the r  
than  p a r o x y s m a l  hype r t ens ion  and  m o r e  usua l ly  have  
b i la te ra l  adrena l ,  ex t r a - ad rena l  or  mul t i - foca l  t umours .  
The  prevalence  o f  m a l i g n a n t  t u m o u r s  has  p r o b a b l y  been 
unde re s t ima ted  in the past .  The  need  for  l i fe long fol low- 
up  is unde r sco red  since pa t i en t  a n d  t u m o u r  charac te r i s -  
tics a t  p r e sen t a t i on  (o ther  than  p r i m a r y  t u m o u r  size 
> 5 cm for  ad rena l  t u m o u r s )  are  p o o r  p red ic to r s  o f  the 
la ter  d e v e l o p m e n t  o f  mul t i -cen t r ic  or  m a l i g n a n t  disease.  
The  usual  b iochemica l  tests (pa r t i cu la r ly  p l a s m a  and  uri-  
na ry  ca t echo lamine  levels) a p p e a r  to be as d iagnos t i ca l ly  
rel iable  as in the  adu l t  p o p u l a t i o n .  W h o l e - b o d y  scintig- 
r a p h y  wi th  131I-mIBG is an  eff icacious,  non- invas ive ,  
local is ing p rocedure ,  pa r t i cu l a r ly  for  ex t ra -adrena l ,  mul-  
t i - focal  or  me tas t a t i c  m a l i g n a n t  tumours .  13~I-mIBG 
t he r apy  has  a l imi ted  role bu t  m a y  be cons ide red  as  
a pa l l ia t ive  measu re  when  a l te rna t ives  have  failed.  
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